Heparin Glycan Microarray for Screening

Information

  • Research Project
  • 7421026
  • ApplicationId
    7421026
  • Core Project Number
    R41RR023764
  • Full Project Number
    5R41RR023764-02
  • Serial Number
    23764
  • FOA Number
    PA-06-29
  • Sub Project Id
  • Project Start Date
    5/15/2007 - 17 years ago
  • Project End Date
    4/30/2010 - 14 years ago
  • Program Officer Name
    HEART, LUNG, AND BLOOD INST., NATIONAL
  • Budget Start Date
    5/1/2008 - 16 years ago
  • Budget End Date
    4/30/2010 - 14 years ago
  • Fiscal Year
    2008
  • Support Year
    2
  • Suffix
  • Award Notice Date
    5/2/2008 - 16 years ago

Heparin Glycan Microarray for Screening

[unreadable] DESCRIPTION (provided by applicant): The proposed research program applies Solidus technology in microarraying, biocatalysis, and screening and the Linhardt group's expertise in heparin/heparan sulfate to the field of glycomics. Glycomics, the comprehensive study of glycan structure-function relationship, is a sub-discipline of metabolomics and the next step beyond genomics and proteomics. Heparin glycosaminoglycans (heparin and heparan sulfate) are among the most structural complex biopolymers. These glycans carry and store significant biological information crucial in virtually all pathological and pathophysiological processes involving cell-cell interaction and communication. The specific aims and milestones of this Phase I STTR proposal are to: 1. prepare a heparin glycan microarray; 2. probe this microarray with the highly specific heparin-binding protein, antithrombin III; 3. prepare an enzyme-modified heparosan microarray; 4. probe this microarray with a collection of heparin-binding proteins to examine binding specificity; and 5. prepare a structurally defined glycan microarray based on the glycosyltransferase extension, and enzymatic modification of heparosan oligosaccharide acceptors for probing with heparin-binding proteins. Phase I will focus on developing the core technology required for developing a HepGly chip as a glycomics platform for screening interactions with heparin-binding proteins. Potential applications for a HepGly microarray include the development of the next generation of heparin-based drugs, the evaluation small molecule drugs that antagonize with heparin/heparan sulfate interaction with heparin-binding proteins and the rapid screening of biological samples in diagnostic applications. A phase II proposal will be prepared to develop these commercial applications. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL CENTER FOR RESEARCH RESOURCES
  • Activity
    R41
  • Administering IC
    RR
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    200000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    389
  • Ed Inst. Type
  • Funding ICs
    NCRR:200000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SOLIDUS BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
    173649075
  • Organization City
    TROY
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    121803511
  • Organization District
    UNITED STATES